Beijing Scitop Bio-tech Co (300858) Q3 2026 earnings summary

Executive summary

• Q3 revenue was RMB97.14m, down 6.63% YoY; net income attributable to shareholders was RMB10.66m, down 69.57%.

• 9M revenue was RMB266.65m, down 0.28% YoY; net income was RMB35.75m, down 53.10%.

Financial highlights

• 9M adjusted net income, excluding non-recurring gains and losses, was RMB25.25m, down 62.36% YoY; Q3 adjusted net income was RMB6.57m, down 79.44%.

• 9M operating profit was RMB38.55m versus RMB88.51m in 9M 2025; income tax expense fell to RMB2.73m from RMB12.26m.

• 9M operating cash flow was RMB31.61m, down 56.46% YoY; investing cash flow was RMB141.90m versus an outflow of RMB40.08m in 9M 2025.

Key financial ratios and metrics

• Q3 basic and diluted EPS were RMB0.04, each down 69.23% YoY; 9M basic and diluted EPS were RMB0.14, each down 51.72%.

• Weighted average ROE was 0.60% for Q3, down 1.34 percentage points YoY, and 1.95% for 9M, down 2.25 points.

• Total assets were RMB1,973.63m at Sep. 30, down 2.24% from year-end 2025; shareholder equity was RMB1,761.79m, down 4.40%.